Company Deep Dive
Read the full research report: business segments breakdown, earnings transcripts review, management credibility analysis, competitive landscape, and scenarios.
GLPG.AS
HoldSecond WindLakefront Biotherapeutics NV · Healthcare · Belgium · $1.8B · Avg Vol: $3M/d
COMPANY DESCRIPTION
Galapagos NV is a clinical-stage biotechnology company dedicated to discovering and developing novel medicines with new mechanisms of action, primarily in inflammation, fibrosis, and kidney diseases. The company's competitive moat is built on its proprietary target discovery platform and robust R&D capabilities, generating a pipeline of potential first-in-class therapies and validated through strategic pharmaceutical collaborations.
FINANCIAL SUMMARY (EUR)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM |
|---|---|---|---|---|---|---|---|
| Revenue | 234.4M | 241.2M | 239.7M | 275.6M | 1.1B | 47.6% | — |
| EPS (EUR) | -1.58 | -3.32 | 3.21 | 1.12 | 4.87 | 23.2% | 4.77 |
| Shares | 65.6M | 65.8M | 65.9M | 65.9M | 65.9M | +0.5% | — |
| Debt | 26.9M | 21.9M | 9.6M | 11.7M | 6.9M | -28.8% | — |
| Equity | 2.6B | 2.5B | 2.8B | 2.9B | 3.2B | 5.2% | — |
| Op CF | -503.8M | -500.5M | -406.0M | -320.0M | -257.5M | — | — |
| Inv CF | 541.2M | -1.2B | 71.2M | 220.6M | 288.8M | — | — |
| Fin CF | -3.9M | -1.5M | -5.0M | -4.9M | -3.3M | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of GLPG.AS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| GLPG.AS | Lakefront Biotherapeutics NV(you) | $1.8B | — | Hold |
| AGMB | AgomAb Therapeutics NV | $649M | 14 | Strong Sell |
| TUB.BR | Financière de Tubize SA | $9.6B | 27 | Sell |
| HYL.BR | Hyloris Pharmaceuticals SA | $143M | 13 | Strong Sell |
| UCB.BR | UCB SA | $47.8B | 79 | Buy |
| FAGR.BR | Fagron NV | $1.9B | 80 | Strong Buy |
| IBAB.BR | Ion Beam Applications SA | $567M | 60 | Hold |
| NYXH | Nyxoah SA | $163M | 10 | Strong Sell |
| MDXH | MDxHealth SA | $69M | 11 | Strong Sell |
| SEQUA.BR | Sequana Medical NV | $54M | 10 | Strong Sell |
Peer medians: ROE -8.3% · P/E 19.0x · Gross margin 60.2%